141 related articles for article (PubMed ID: 1115054)
1. Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.
Hepner GW; Vesell ES
Am J Dig Dis; 1975 Jan; 20(1):9-12. PubMed ID: 1115054
[TBL] [Abstract][Full Text] [Related]
2. Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.
Vesell ES; Shapiro JR; Passananti T; Jorgensen H; Shively CA
Clin Pharmacol Ther; 1975 Jan; 17(1):48-56. PubMed ID: 1122669
[TBL] [Abstract][Full Text] [Related]
3. Unaltered metabolism of antipyrine and tolbutamide in fasting man.
Reidenberg MM; Vesell ES
Clin Pharmacol Ther; 1975 Jun; 17(6):650-6. PubMed ID: 1139856
[TBL] [Abstract][Full Text] [Related]
4. Saliva and plasma clearance of antipyrine as reflectors of liver function.
Luoma PV; Sotaniemi EA
Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
[TBL] [Abstract][Full Text] [Related]
5. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
[TBL] [Abstract][Full Text] [Related]
6. Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
Bach B; Hansen JM; Kampmann JP; Rasmussen SN; Skovsted L
Clin Pharmacokinet; 1981; 6(5):389-96. PubMed ID: 7333060
[TBL] [Abstract][Full Text] [Related]
7. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.
Elin RJ; Vesell ES; Wolff SM
Clin Pharmacol Ther; 1975 Apr; 17(4):447-57. PubMed ID: 1122686
[TBL] [Abstract][Full Text] [Related]
8. Microsomal enzymes in patients with gastric carcinoma as determined by plasma half-life of antipyrine.
Higuchi T; Nakamura T; Uchino H
Gan; 1978 Dec; 69(6):753-6. PubMed ID: 750270
[TBL] [Abstract][Full Text] [Related]
9. Comparison of rate of hepatic metabolism in vitro and half-life for antipyrine in vivo in three species.
McManus ME; Ilett KF
Xenobiotica; 1979 Feb; 9(2):107-18. PubMed ID: 433309
[TBL] [Abstract][Full Text] [Related]
10. Liver failure and drug metabolism.
Andreasen PB; Ranek L
Scand J Gastroenterol; 1975; 10(3):293-7. PubMed ID: 1138332
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary disease and antipyrine clearance.
Laybourn C; Tønnesen P; Loft S; Sonne J; Døssing M
Clin Pharmacol Ther; 1986 Oct; 40(4):415-9. PubMed ID: 3489577
[TBL] [Abstract][Full Text] [Related]
12. Antipyrin clearance in homozygous beta-thalassemia.
Rifkind AB; Canale V; New MI
Clin Pharmacol Ther; 1976 Oct; 20(4):476-83. PubMed ID: 975719
[TBL] [Abstract][Full Text] [Related]
13. Microsomal enzymes in patients with acute leukemia as determined by plasma half-life of antipyrine.
Higuchi T; Nakamura T; Uchino H
Cancer Chemother Pharmacol; 1980; 5(1):55-9. PubMed ID: 6936094
[TBL] [Abstract][Full Text] [Related]
14. Microsomal metabolism of antipyrine in rats treated with antineoplastic drugs.
Slørdal L; Høyem-Johansen T; Aarbakke J
Pharmacology; 1983; 26(2):95-9. PubMed ID: 6844394
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.
Boobis AR; Brodie MJ; Kahn GC; Toverud EL; Blair IA; Murray S; Davies DS
Br J Clin Pharmacol; 1981 Dec; 12(6):771-7. PubMed ID: 7340879
[TBL] [Abstract][Full Text] [Related]
16. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
[TBL] [Abstract][Full Text] [Related]
17. Variation of microsomal mixed function oxidase(s) and human lung cancer.
Kellermann G; Jett JR; Luyten-Kellermann M; Moses HL; Fontana RS
Cancer; 1980 Mar; 45(6):1438-42. PubMed ID: 7357525
[TBL] [Abstract][Full Text] [Related]
18. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
[TBL] [Abstract][Full Text] [Related]
19. Ibuprofen does not impair antipyrine clearance.
Abernethy DR; Greenblatt DJ
J Clin Pharmacol; 1983; 23(11-12):517-22. PubMed ID: 6662976
[TBL] [Abstract][Full Text] [Related]
20. Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.
Luoma PV; Sotaniemi EA; Pelkonen RO; Arranto A; Ehnholm C
Eur J Clin Pharmacol; 1982; 23(3):275-82. PubMed ID: 7173298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
